Ind Swift Laboratories Ltd vs Mono Pharmacare Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 14, 2026

Key Highlights

The Latest Trading Price of Ind-Swift Laboratories Ltd is ₹ 162.9 as of 12 Jun 15:30 . The P/E Ratio of Ind-Swift Laboratories Ltd changed from 6.9 on March 2023 to 2.3 on March 2025 . This represents a CAGR of -30.66% over 3 yearsThe P/E Ratio of Mono Pharmacare Ltd changed from 32 on March 2024 to 13.2 on March 2025 . This represents a CAGR of -35.77% over 2 years The Market Cap of Ind-Swift Laboratories Ltd changed from ₹ 425.72 crore on March 2021 to ₹ 509.08 crore on March 2025 . This represents a CAGR of 3.64% over 5 yearsThe Market Cap of Mono Pharmacare Ltd changed from ₹ 77.92 crore on March 2024 to ₹ 40.81 crore on March 2025 . This represents a CAGR of -27.63% over 2 years The revenue of Ind-Swift Laboratories Ltd for the Mar '26 is ₹ 172.01 crore as compare to the Dec '25 revenue of ₹ 178.43 crore. This represent the decline of -3.6% The revenue of Mono Pharmacare Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Ind-Swift Laboratories Ltd for the Mar '26 is ₹ 17.64 crore as compare to the Dec '25 ebitda of ₹ 25.9 crore. This represent the decline of -31.89% The ebitda of Mono Pharmacare Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Ind-Swift Laboratories Ltd changed from ₹ 1.01 crore to ₹ 15.11 crore over 8 quarters. This represents a CAGR of 286.79% The net profit of Mono Pharmacare Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The Dividend Payout of Ind-Swift Laboratories Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Mono Pharmacare Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Ind-Swift Laboratories Ltd

Ind-Swift Laboratories Limited is a part of the Ind-Swift Group and is based at Chandigarh, Punjab, India.
The Company is one of the leading manufacturers of APIs catering to global and domestic formulators.
Based in Chandigarh, India, the Company operated two advanced manufacturing facilities in Derabassi and Jammu, adhering to international standards.
Ind-Swift Laboratories Ltd. is recognised globally as a leader in the Macrolide Antibiotic sector, and its products are well-regarded by major pharmaceutical formulators worldwide. Ind-Swift Laboratories Limited was incorporated on January 4, 1995 as a joint venture between Ind-Swift Ltd and Punjab State Industrial Development Corporation.
Later, Ind-Swift purchased Punjab State Industrial Development Corporation equity to emerge as a single largest shareholder in the company.

About Mono Pharmacare Ltd

Mono Pharmacare Limited was originally formed as a Partnership Firm in the name and style of 'M/s.
Mono Chemist' through Partnership Deed dated May 06, 1994.
The Partnership Firm was then converted into Public Limited company in the name of Mono Pharmacare Limited vide Certificate of Incorporation dated October 17, 2022, was issued by the Registrar of Companies, Ahmedabad.
The Company is engaged in the business of marketing and distribution of pharmaceutical products. The product portfolio comprises of a wide range of drugs like Antibiotics, Antifungal, Anti CoughCold & Anti-allergic, Antacid and Antiemetics, Analgesics and Antipyretics, Nutraceuticals, Skincare, Antiseptic, Cardiac and Diabetic & Cosmetics etc. getting products manufactured through contract manufacturing. Supal Distributors LLP, a Partnership Firm, was incorporated on November 24, 2016, with the Promoters of Company, Panilam Lakhatariya and Supal Lakhatariya, being the Original Partners.

FAQs for the comparison of Ind-Swift Laboratories Ltd and Mono Pharmacare Ltd

Which company has a larger market capitalization, Ind-Swift Laboratories Ltd or Mono Pharmacare Ltd?

Market cap of Ind-Swift Laboratories Ltd is 1,416 Cr while Market cap of Mono Pharmacare Ltd is 20 Cr

What are the key factors driving the stock performance of Ind-Swift Laboratories Ltd and Mono Pharmacare Ltd?

The stock performance of Ind-Swift Laboratories Ltd and Mono Pharmacare Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Ind-Swift Laboratories Ltd and Mono Pharmacare Ltd?

As of June 14, 2026, the Ind-Swift Laboratories Ltd stock price is INR ₹162.9. On the other hand, Mono Pharmacare Ltd stock price is INR ₹11.65.

How do dividend payouts of Ind-Swift Laboratories Ltd and Mono Pharmacare Ltd compare?

To compare the dividend payouts of Ind-Swift Laboratories Ltd and Mono Pharmacare Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.